Share This Page
Bulk Pharmaceutical API Sources for CUBICIN
✉ Email this page to a colleague
Bulk Pharmaceutical API Sources for CUBICIN
| Vendor | Vendor Homepage | Vendor Sku | API Url |
|---|---|---|---|
| TCI (Tokyo Chemical Industry) | ⤷ Start Trial | D4229 | ⤷ Start Trial |
| AbaChemScene | ⤷ Start Trial | CS-1857 | ⤷ Start Trial |
| MedChemexpress MCE | ⤷ Start Trial | HY-B0108 | ⤷ Start Trial |
| AvaChem Scientific | ⤷ Start Trial | 103060-53-3 | ⤷ Start Trial |
| AvaChem Scientific | ⤷ Start Trial | 2335 | ⤷ Start Trial |
| BOC Sciences | ⤷ Start Trial | 103060-53-3 | ⤷ Start Trial |
| >Vendor | >Vendor Homepage | >Vendor Sku | >API Url |
Bulk Active Pharmaceutical Ingredient (API) Sources for CUBICIN (Daptomycin)
Introduction
CUBICIN, a leading antibiotic used to treat serious Gram-positive infections, contains the active pharmaceutical ingredient (API) daptomycin. Its efficacy hinges on the consistent quality and reliable supply of high-grade API. This article explores the primary sources for bulk daptomycin, assessing their manufacturing capabilities, regulatory compliance, and market dynamics. With a focus on ensuring pharmaceutical supply chain resilience, understanding these API sources is crucial for stakeholders in the antimicrobial sector.
Overview of Daptomycin as a Critical API
Daptomycin, a cyclic lipopeptide antibiotic, was first approved by the U.S. Food and Drug Administration (FDA) in 2003. Its mechanism involves binding to bacterial membranes, resulting in rapid depolarization and cell death. Given its potency against multidrug-resistant Gram-positive pathogens such as MRSA and VRE, the demand for high-quality daptomycin has surged globally.
The API's complex synthesis, involving fermentation followed by chemical modifications, demands sophisticated manufacturing infrastructure. Since its introduction, several manufacturers have scaled production to meet escalating global needs.
Major API Manufacturers of Daptomycin
1. Merck KGaA / EMD Serono
Overview: Merck KGaA, operating globally under the EMD Serono brand, pioneered the commercial production of daptomycin. Their robust GMP-compliant manufacturing facilities produce the API sourced for CUBICIN.
Manufacturing Capabilities: With extensive fermentation facilities, Merck's production process involves fermentation of Streptomyces roseosporus, followed by meticulous purification techniques, ensuring high-potency API quality.
Regulatory Standing: As the original supplier, Merck’s API conforms with FDA, EMA, and other major regulatory authorities, enabling a seamless supply chain for U.S. and EU markets.
Market Position: The primary API supplier for CUBICIN, with a long-standing reputation for quality and supply consistency.
2. Luye Pharma
Overview: Luye Pharma, a Chinese biopharmaceutical entity, has expanded its portfolio to include daptomycin. Through significant investment in fermentation and chemical synthesis processes, Luye aims to serve both domestic and international markets.
Manufacturing Capabilities: Their facilities utilize advanced fermentation technology, with multiple GMP-compliant sites producing bulk API for export.
Regulatory Status: Currently, Luye's API holds approvals in certain jurisdictions, with ongoing efforts to obtain broader regulatory clearances for export markets.
Market Position: As a potential secondary source, Luye offers a cost-competitive alternative, aiding in supply diversification.
3. Zhejiang Hisun Pharmaceutical Co., Ltd.
Overview: Hisun Pharmaceuticals, based in China, is developing capabilities for daptomycin API, leveraging fermentation technology and extensive R&D.
Manufacturing Capabilities: Their manufacturing process involves fermentation of Streptomyces roseosporus, with chemical modifications to produce API at scale.
Regulatory Compliance: While currently focusing on domestic markets, Hisun has received approvals from Chinese regulatory authorities and is working towards international standards.
Market Position: Positioned as an emerging API source, with potential for supply diversification contingent on regulatory approvals.
Emerging and Potential API Suppliers
4. WuXi AppTec
Overview: WuXi AppTec, a leading Contract Development and Manufacturing Organization (CDMO), offers development pathways for daptomycin API, supporting contract manufacturing and scale-up.
Capabilities: While primarily a CDMO, WuXi possesses fermentation and purification expertise to support custom API scale-up, potentially becoming a supplier in the future.
Regulatory Standing: As a trusted CDMO, WuXi meets global GMP standards, but direct commercialization rights depend on client agreements.
5. Other Contract Manufacturers
Several smaller Chinese and Indian pharmaceutical entities are investing in developing daptomycin API, focusing on fermentation process optimization and regulatory pathways for broader market access.
Market Dynamics and Supply Chain Considerations
Regulatory and Quality Assurance: Merchants sourcing daptomycin API predominantly rely on established manufacturers like Merck. Regulatory approval, cGMP compliance, and consistent batch quality remain critical.
Supply Chain Risks: Dependence on limited suppliers can create vulnerabilities. Diversification through multiple API sources minimizes risk, especially amid global supply chain disruptions.
Cost Factors: Chinese and Indian manufacturers often offer competitive pricing, impacting procurement strategies, particularly for regions with cost-sensitive healthcare systems.
Manufacturing Complexity: The complexity of fermentation and purification processes constrains rapid capacity expansion. Suppliers with advanced fermentation technology and proven GMP compliance are preferred.
Quality Assurance and Regulatory Compliance
Ensuring API quality aligns with pharmacopeial standards, including USP, EP, or other regional monographs. Manufacturers must demonstrate batch-to-batch consistency, impurity profiles, and stability data compliant with regulatory expectations.
Regulatory authorities may require site inspections, validation data, and stability studies before approving bulk API imports. Vendors with established approvals streamline supply continuity.
Future Outlook for Daptomycin API Sources
The landscape is increasingly competitive, with Chinese and Indian API producers investing to meet the burgeoning demand. Merck’s continued dominance ensures stability but emphasizes the importance of diversification.
Emerging technologies focusing on fermentation process improvements could reduce production costs and enhance supply robustness. Regulatory harmonization efforts, including WHO prequalification, could expand access to quality-assured APIs in emerging markets.
Conclusion
The primary bulk API source for CUBICIN remains Merck KGaA, given its established manufacturing infrastructure and regulatory compliance. However, Chinese manufacturers like Luye Pharma and Zhejiang Hisun are positioning themselves as viable secondary sources, with the potential to diversify supply chains and reduce costs.
Supply chain resilience depends on balancing quality, regulatory alignment, and market dynamics. Stakeholders should monitor emerging API suppliers, technological advancements, and global regulatory developments to secure uninterrupted access to high-quality daptomycin.
Key Takeaways
- Dominant Source: Merck KGaA remains the primary, most reliable supplier of daptomycin API for CUBICIN.
- Emerging Competition: Chinese manufacturers, especially Luye Pharma and Hisun Pharmaceuticals, are expanding API production capacity, offering cost-effective alternatives.
- Supply Chain Resilience: Diversification of API sources mitigates risks associated with geopolitical and logistical disruptions.
- Regulatory Alignment: Suppliers with established regulatory approvals ensure faster, smoother market access.
- Technological Trends: Advances in fermentation and purification processes can reduce costs and increase API quality consistency.
FAQs
1. What are the main challenges associated with sourcing daptomycin API?
Manufacturing the complex cyclic lipopeptide involves sophisticated fermentation and chemical processes requiring strict quality controls. Variability in fermentation yields, regulatory compliance, and geopolitical factors also pose risks.
2. Can secondary API suppliers meet the same quality standards as Merck?
Yes, several Chinese and Indian manufacturers adhere to GMP standards. However, thorough qualification and regulatory validation are essential to ensure comparable quality.
3. How does API source diversification impact CUBICIN supply security?
Diversification reduces reliance on a single supplier, decreasing vulnerability to supply disruptions, regulatory delays, or manufacturing issues.
4. Are there regulatory hurdles for non-Merck API suppliers?
Yes, non-Merck suppliers must demonstrate compliance with international cGMP standards and secure approvals from authorities such as the FDA or EMA, which can be time-consuming.
5. What trends could influence future API sourcing for CUBICIN?
Emerging process innovations, global regulatory harmonization, and increased manufacturing capacity in emerging markets are likely to influence sourcing strategies, potentially leading to more diversified and resilient supply chains.
Sources
[1] U.S. Food and Drug Administration. CUBICIN (daptomycin) prescribing information.
[2] Merck KGaA Annual Reports.
[3] Luye Pharma Group Annual Reports and regulatory filings.
[4] Zhejiang Hisun Pharmaceutical Co., Ltd. Regulatory documentation.
[5] WHO Prequalification Program documentation on antimicrobial APIs.
More… ↓
